GlobeNewswire Inc | Nov 1, 2021 08:00AM EDT

November 01, 2021

WOBURN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in OncologyPanel: Pioneering the Next Generation of Oncolytic Virus TherapeuticsDate: Monday, November 8, 2021Time: 12:45 pm ET

Piper Sandler 33rd Virtual Annual Healthcare ConferenceDate: Tuesday, November 30 through Thursday, December, 2021A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22nd at 10:00 am ET

A simultaneous webcast and replay of the fireside chat at the Piper Sandler 33rd Annual Healthcare Conference will also be available in the Investors section of Replimunes website at www.replimune.com.

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimunes Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.For more information, please visit www.replimune.com.

Investor Inquiries Chris BrinzeyICR Westwicke339.970.2843chris.brinzey@westwicke.com

Media InquiriesLissette SteeleVerge Scientific Communications202.930.4762 x 409lsteele@vergescientific.com